IL1B and Respiratory tract infection: Four patients (3 FMF and 1 TRAPS) (6.2%) discontinued canakinumab after the first injection: two due to AEs (respiratory tract infections) and two due to other reasons (weight gain and post-renal transplantation infection risk with IL-1 inhibitors).